FindTrial
Sign In

KN026

DRUG10 trials

Sponsors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Peking University Cancer Hospital & Institute, Peking University, Shanghai JMT-Bio Inc., CSPC Megalith Biopharmaceutical Co.,Ltd.

Conditions

Advanced Breast CancerBreast CancerEarly or Locally Advanced HER2-positive Breast CancerGastric CancerGastric/Gastroesophageal Junction CancerHER2-positive Biliary Tract CancerHER2-positive Colorectal CancerHER2-positive Gastric Cancer

Phase 1

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
CompletedNCT03619681
Jiangsu Alphamab Biopharmaceuticals Co., LtdBreast Cancer, Gastric Cancer
Start: 2018-09-17End: 2022-08-26Updated: 2024-03-12
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
NCT03847168
Jiangsu Alphamab Biopharmaceuticals Co., LtdBreast Cancer, Gastric/Gastroesophageal Junction Cancer
Start: 2019-06-18End: 2022-12-31Updated: 2021-11-17

Phase 2

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
NCT04881929
Jiangsu Alphamab Biopharmaceuticals Co., LtdBreast Cancer
Start: 2021-08-09End: 2023-02-15Target: 30Updated: 2022-06-22
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Not yet recruitingNCT05985707
Peking University Cancer Hospital & InstituteHER2-positive Biliary Tract Cancer, HER2-positive Colorectal Cancer
Start: 2023-08-15End: 2026-12-31Target: 80Updated: 2023-08-21
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
RecruitingNCT06023758
Peking UniversityHER2-positive Locally Advanced Resectable Gastric Cancer
Start: 2023-09-22End: 2026-12-31Target: 18Updated: 2024-05-10
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
Not yet recruitingNCT06998771
Shanghai JMT-Bio Inc.HER2-positive Gastric Cancer
Start: 2025-06-15End: 2029-12-31Target: 153Updated: 2025-05-31
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Not yet recruitingNCT07332533
Shanghai JMT-Bio Inc.HER2-positive Gastric Cancer
Start: 2025-12-30End: 2032-12-31Target: 490Updated: 2026-01-12
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
Not yet recruitingNCT07597629
CSPC Megalith Biopharmaceutical Co.,Ltd.Advanced Breast Cancer
Start: 2026-05-30End: 2029-05-30Target: 114Updated: 2026-05-19

Phase 3

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
RecruitingNCT06747338
Shanghai JMT-Bio Inc.Early or Locally Advanced HER2-positive Breast Cancer
Start: 2024-12-16End: 2027-12-16Target: 520Updated: 2025-04-24
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
RecruitingNCT07441460
Shanghai JMT-Bio Inc.Resectable HER2-positive Breast Cancer
Start: 2026-03-06End: 2035-08-07Target: 1800Updated: 2026-04-08

Related Papers

PRELIMINARY SAFETY, EFFICACY AND PHARMACOKINETICS (PK) RESULTS OF KN026 (A HER2 BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED SOLID TUMOR PATIENTS WITH HER2 EXPRESSION
Antibody Therapeutics2023-07-01
Abstract OT2-16-04: KN026 in combination with docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer: A single arm, multicenter, phase 2 study
Cancer Research2023-03-011 citations
Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer.
Journal of Clinical Oncology2020-05-2017 citations